PYC Therapeutics says safety review committee approves dose escalation to patient cohort

Latest News

PYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee (SRC) governing one of its phase 1 clinical trials has approved the escalation of dosing to patient cohort 2.

The company is developing precision therapies for patients with genetic diseases. One of its assets is a first-in-class drug candidate currently progressing through a phase 1 clinical trial for patients with a blinding eye disease called Retinitis Pigmentosa type 11 (RP11).

The approval of the dose escalation follows a review of the four-week safety and tolerability data from the first cohort of patients dosed with the investigational drug candidate.

PYC said it will now proceed to enrolment and dosing of patients in the second dose cohort evaluating a dose of 10 micrograms of the investigational drug in patients with RP11.

Subject to SRC approval, PYC said it remains on track to complete dosing for patients in cohorts 2 and 3 before the end of 2023.

PYC added that is expects to transition to a Phase 2 multi-dose study beginning in the middle of next year on successful completion of the ongoing Phase 1 study.